Thai CV Risk Score and Primary Prevention in Impaired Fasting Plasma Glucose or Diabetes Mellitus versus Normoglycemia in Patients with Metabolic Syndrome
Abstract
Background: Impaired fasting plasma glucose (IFG) as well as diabetes mellitus (DM) may influence the presence of another metabolic syndrome (MetS) components resulting in the different risk of cardiovascular (CV) morbidity and mortality. This study aimed to determine the impact of IFG as well as DM on the 10‑year CV risk using Thai CV risk score and primary prevention in complying with CV risk score in these patients.
Methods: This cross‑sectional study was conducted at the internal medicine clinic, Pathum Thani Hospital, Thailand. The study was approved by the hospital ethics committee and written informed consent was obtained from all patients. Patients having MetS according to the criteria of the International Diabetes Federation were enrolled while those with a history of CVD were excluded. The 10‑year CV risk was assessed using the Thai CV risk score.
Results: The total of 112 patients were enrolled in the study. They were in old age and female sex was a significantly higher proportion (61.70% vs 35.50%, P = 0.013). Of these, 72.32% had IFG or DM. Proportions of patients with moderate and high CV risk score were significantly greater in IFG/DM group and only 34.48% and 79.31% of patients with moderate or high CV risk score received aspirin and statin. IFG or DM significantly elevated CV risk score (OR = 6.66, 95% CI = 2.29, 19.58).
Conclusions: IFG/DM significantly elevated CV risk score in these patients with the strongest impact. The assessment of CV risk is highly recommended for primary prevention and long‑term CVD benefit.
Keywords
Full Text:
PDFReferences
International Diabetes Federation. The IDF consensus worldwide
definition of the metabolic syndrome; c2006. Available form:
http://www.idf. org/webdata/docs/IDF_Meta_def_final.pdf.
Published. [Last cited on 2018 Aug 5].
Aekplakorn W, Chongsuvivatwong V, Tatsanavivat P,
Suriyawongpaisal P. Prevalence of metabolic syndrome defined
by the International diabetes federation and National cholesterol
education program criteria among Thai adults. Asia Pac J Public
Health 2011;23:792‑800.
Morales DD, Punzalan FE, Paz‑Pacheco E, Sy RG,
Duante CA. Metabolic syndrome in the Philippine general
population: Prevalence and risk for atherosclerotic
cardiovascular disease and diabetes mellitus. Diab Vasc Dis
Res 2008;5:36‑43.
Yen YF, Hu HY, Lin IF, Lai YJ, Su VY, Pan SW, et al.
Associations of metabolic syndrome and its components with
mortality in the elderly: A cohort study of 73,547 Taiwanese
adults. Medicine 2015;94:1‑9.
Hidaka T, Hayakawa T, Kakamu T, Kumagai T, Hiruta Y, Hata J,
et al. Prevalence of metabolic syndrome and its components
among Japanese workers by clustered business category. PLoS
One 2016;11:1‑11.
World Health Organization. Definition and diagnosis of diabetes
mellitus and intermediate hyperglycemia: Report of a WHO/IDF
consultation [Internet]; c2006. Available form: http://www.who.
int/diabetes/publications/Definition%20and%20diagnosis%20
of%20diabetes_new.pdf. [Last cited on 2018 Jan 31].
Rosa SD, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C,
Daniela P, et al. Type 2 diabetes mellitus and cardiovascular disease: Genetic and epigenetic links. Front Endocrinol
(Lausanne) 2018;9:2.
Kim M, Kim M, Huang L, Jee SH, Le JH. Genetic risk score of
common genetic variants for impaired fasting glucose and newly
diagnosed type 2 diabetes influences oxidative stress. Sci Rep
;8:7828.
American Diabetes Association, Standards of medical care in
diabetes 2018. Diabetes Care 2018;41:S3‑157.
Pongchaiyakul C, Nguyen TV, Kosulwat V, Rojroongwasinkul N,
Charoenkiatkul S, Pongchaiyakul C, et al. Defining obesity by
body mass index in the Thai population: An epidemiologic study.
Asia Pac J Clin Nutr 2006;15:293‑9.
Sharma SK, Ghimire A, Radhakrishnan J, Thapa L, Shrestha NR,
Paudel N, et al. Prevalence of hypertension, obesity, diabetes, and
metabolic syndrome in Nepal. Int J Hypertens 2011;2011:1‑9.
Klein BE, Klein R, Lee KE. Components of the metabolic
syndrome and risk of cardiovascular disease and diabetes in
beaver dam. Diabetes care 2002;25:1790‑4.
Berezin A. Metabolic memory phenomenon in diabetes
mellitus: Achieving and perspectives. Diabetes Metab Syndr
;10:S176‑83.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.
‑year follow‑up of intensive glucose control in type 2 diabetes.
N Engl J Med 2008;359:1577‑89.
Rachas A, Raffaitin C, Barberger‑Gateau P, Helmer C, Ritchie K,
Tzourio C, et al. Clinical usefulness of the metabolic syndrome
for the risk of coronary heart disease does not exceed the sum
of its individual components in older men and women. The
Three‑City (3C) study. Heart 2012;98:650‑5.
Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, et al.
Impaired fasting glucose and risk of cardiovascular disease in
Korean men and women: The Korean heart study. Diabetes Care
;36:328‑35.
Putadechakum S, Leelahakul V, Rodjinda P, Phanachet P,
Roongpisuthipong C. Cardiovascular risk factors and 10‑year risk
for coronary heart disease in Thai adults. Int J Sci Res 2014;4:1‑7.
Peykari N, Saeedi Moghaddam S, Djalalinia S, Kasaeian A,
Sheidaei A, Mansouri A, et al. High fasting plasma glucose
mortality effect: A comparative risk assessment in 25‑64 years
old Iranian population. Int J Prev Med 2016;7:75.
Udenze IC, Amadi CE. Cardiovascular disease risk assessment
in Nigerian adults with type 2 diabetes and metabolic syndrome
using the Framingham’s risk score. Int J Non‑Commun Dis
;3:15‑20.
Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J,
Sandesara P, et al. Socioeconomic status and cardiovascular
outcomes. Circulation 2018;137:2166‑78.
Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM,
Heine RJ, Horton ES, Primary prevention of cardiovascular
disease and type 2 diabetes in patients at metabolic risk: An
endocrine society clinical practice guideline. J Clin Endocrinol
Metab 2008;93:3671‑89.
Bibbins-Domingo K. Statin use for the primary prevention
of cardiovascular disease in adults, US Preventive
Services Task Force Recommendation statement. JAMA
;316:1997-2007.
Zhan Y, Yu J, Chen R, Gao J, Ding R, Fu Y, et al. Socioeconomic
status and metabolic syndrome in the general population of
China: A cross‑sectional study. BMC Public Health 2012;12:921.
Verma P, Srivastava RK, Jain D. Association of lifestyle risk
factors with metabolic syndrome components: A cross‑sectional
study in Eastern India. Int J Prev Med 2018;9:6.